Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.00 Average Price Target from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned an average recommendation of “Hold” from the six brokerages that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $9.00.

Several research analysts have issued reports on the stock. StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 25th. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Aclaris Therapeutics during the first quarter valued at approximately $39,000. SG Americas Securities LLC boosted its position in shares of Aclaris Therapeutics by 69.5% in the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 13,461 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Aclaris Therapeutics by 5,265.1% in the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 61,602 shares in the last quarter. Deuterium Capital Management LLC acquired a new position in Aclaris Therapeutics during the 1st quarter valued at about $99,000. Finally, Marquette Asset Management LLC acquired a new position in Aclaris Therapeutics during the 1st quarter valued at about $104,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ ACRS opened at $2.09 on Wednesday. Aclaris Therapeutics has a 52-week low of $0.59 and a 52-week high of $5.70. The firm has a market capitalization of $149.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.10. The stock has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.22.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The business had revenue of $2.77 million during the quarter, compared to analysts’ expectations of $1.74 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. Analysts forecast that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.